Discussing the Growing Role of CDMOs with Anil Kane (DCAT 2023)

Article

Anil Kane, executive director, Global Head of Technical & Scientific Affairs at Thermo Fisher Scientific, discusses the growing role of CDMOs in the biopharma industry

As part of ongoing coverage of DCAT, the PharmTech editors touched base with Anil Kane, executive director, Global Head of Technical & Scientific Affairs at Thermo Fisher Scientific. In in our discussion, Anil discussed various topics within the outsourcing market, including:

  • The increased interest in technologies like cell and gene therapies and oral biologics
  • The continued rise of the "end-to-end" CDMO model and why biopharma partners are seeking it out
  • Recent investments made in new spaces by Thermo Fisher Scientific

For more of our coverage on DCAT in 2023, viewers can visit this page.

Recent Videos
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Buy, Sell, Hold: Cell and Gene Therapy
Related Content